Sign in

    Lachlan

    Research Analyst at William Blair

    Lachlan Hanbury-Brown is an Equity Research Analyst at William Blair, specializing in coverage of biotech companies with a particular focus on the ophthalmology sector. He covers firms such as Tarsus Pharmaceuticals and Apellis Pharmaceuticals, and his performance ranks highly among peers, achieving an 83% success rate and an average return of 11% per recommendation over the past year, with his best call yielding a 26.8% return. Hanbury-Brown began his tenure at William Blair in 2019 and has developed recognized expertise in identifying investment opportunities across the US biotech space. He holds credentials required for equity research analysts and demonstrates a strong track record in the biotechnology field.

    Lachlan's questions to Lyra Therapeutics (LYRA) leadership

    Lachlan's questions to Lyra Therapeutics (LYRA) leadership • Q1 2021

    Question

    Lachlan from William Blair asked about the key gating factors for initiating the Phase 3 trial beyond the FDA meeting, specifically regarding product validation from the CMO. He also inquired about plans for regulatory discussions outside the US for the Phase 3 design.

    Answer

    President and CEO Maria Palasis identified the final protocol submission to the FDA and delivering the clinical product to trial sites as the critical gating items, expressing confidence in the timeline. She stated that the immediate regulatory focus is on the US for the trial, although the company is actively pursuing ex-US partnerships for commercialization. CFO Don Elsey also reiterated that the financial guidance covers the planned Phase 3 and Phase 2 trials.

    Ask Fintool Equity Research AI